AWM
CRSP icon

Activest Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Activest Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$764 Buy
+14
New +$738 ﹤0.01% 1001
2025
Q1 		– Sell
-1
Closed -$42 – 1082
2024
Q4 		$39 Buy
+1
New +$47 ﹤0.01% 776

Other funds holding CRSP

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $792M AUM
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
BIP
Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
IIM
Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Activest Wealth Management's CRSP Position: Q2 2026 in Review

Activest Wealth Management opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 14 shares worth $764. The stake represents ﹤0.01% of the portfolio and ranks #1001 among its holdings. This is a return to the name: Activest Wealth Management previously reported a position in CRSP as recently as Q4 2024.

Activest Wealth Management first reported a position in CRSP in Q4 2024 and has held it in 2 quarters since. 55 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Activest Wealth Management held 14 shares of CRISPR Therapeutics worth $764 as of Q2 2026.
  • CRISPR Therapeutics was a new Activest Wealth Management position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Activest Wealth Management's portfolio in Q2 2026, its #1001 holding.
  • Activest Wealth Management first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 2 quarters since.
  • 55 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Activest Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.